BioSpace News Archive

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines, today announced that it will release its financial results for the quarter ended March 31, 2020 after the market close on May 7 and will also provide a corporate overview and financial results by hosting a conference call

The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2020 of $0.74 per share on outstanding common stock.

The University of Chicago is committed to supporting the rapid development of new technologies and life-saving therapeutics in the battle against the coronavirus pandemic.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, announced the appointment of Noreen R. Henig, MD as its Chief Medical Officer.

Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the stress hormone cortisol, reported its results for the quarter ended March 31, 2020.

SI-BONE, Inc., a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, reported financial results for the quarter ended March 31, 2020.

Enhanced focus on tipifarnib in HRAS mutant HNSCC and KO-539 menin inhibitor in NPM1-mutant and KMT2A(MLL)-rearranged AML

Sientra, Inc., a diversified medical aesthetics company, announced that it will release financial results for the first quarter of 2020 after the close of trading on Monday, May 11, 2020.

Luminex Corporation announced results for its first quarter ended March 31, 2020.

Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Monday, May 11, 2020 at 5:00 p.m.